Valion Bio, Inc. (VBIO) Advances Oral Mucosal Entolimod; Next Test Targets Systemic Exposure
Valion Bio, Inc. and SKL completed formulation of an oral mucosal Entolimod using BioViscid. Valion says a successful program could expand potential U.S. dose needs ~10—40x vs injectable; next study will test for measurable systemic exposure.Material DetailsContext by AI AnalystThis is an early-sta…